Atlas Trials

The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)

Clinical trial NCT06656962 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06656962
Sponsor
Renmin Hospital of Wuhan University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN)
Start date
2024-10-10
Primary completion
2025-12-30
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.